Choice of androgen receptor pathway inhibitors (ARPi) by disease volume and timing of metastases in metastatic hormone sensitive prostate cancer (mHSPC). A phase 1b study of cabozantinib and nivolumab ...
Relevance section written by JCO Associate Editor Gary K. Schwartz, MD, FASCO. The phase Ib COSMIC-021 study evaluated cabozantinib plus atezolizumab in patients with advanced solid tumors. Presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback